We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the... Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. Show more
โ Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate โ โ...
REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.ย (โCoherus,โ NASDAQ: CHRS) today announced that senior management will present at the 43rd Annual J.P. Morgan...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.115 | 10.2678571429 | 1.12 | 1.39 | 1.095 | 2539845 | 1.21791157 | CS |
4 | -0.34 | -21.5873015873 | 1.575 | 1.65 | 1.03 | 2313168 | 1.27017641 | CS |
12 | 0.385 | 45.2941176471 | 0.85 | 2.43 | 0.7 | 5241978 | 1.50528371 | CS |
26 | -0.045 | -3.515625 | 1.28 | 2.43 | 0.6655 | 3651497 | 1.3288136 | CS |
52 | -0.755 | -37.9396984925 | 1.99 | 2.87 | 0.6655 | 2845095 | 1.60791824 | CS |
156 | -10.965 | -89.8770491803 | 12.2 | 14.11 | 0.6655 | 2547191 | 3.68282965 | CS |
260 | -17.925 | -93.5542797495 | 19.16 | 23.03 | 0.6655 | 1924553 | 6.49967169 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions